Scopolamine CAS NO.51-34-3

Min.Order: 10 Milligram
Payment Terms: T/T
Available Specifications:

Product Details

Keywords

Scopolamine
51-34-3
standard supplier in China

Quick Details

ProName: Scopolamine
CasNo: 51-34-3
Molecular Formula: C17H21NO4
Appearance: detailed see specifications
Application: analysis,activity test,Botanical Refer...
DeliveryTime: 1-3?working?days?after?confirming?the?...
PackAge: According to the clients requirement.
Port: China main port
ProductionCapacity: 1 Metric Ton/Day
Purity: ≥98%
Storage: Store at 2~8°C
Transportation: by air or by ocean shipping
LimitNum: 10 Milligram
Plant of Origin: Chinese herbal medicine
Testing Method: NMR/MS/HPLC
Product Ecification: 1mg-1kg
Heavy Metal: <10ppm
Voluntary Standards: company standard
Storage: Store in dry, dark and ventilated plac...
PackAge: Brown vial HDPE plastic bottle

Superiority

Hubei CuiRan Biotechnology Co., Ltd is a leading company in the research, development, manufacture and marketing of High Quality Phytochemicals and Extracts(especially Active Ingredients from Traditional Chinese Medicine，Traditional Chinese Medicine), Natural Active Pharmaceutical Ingredients worldwide. From small quantities for R&D or reference standard, to large quantities for customizing or manufacturing, Biopurify emphasizes on consistent and reliable services for his customers.
With excellent quality products and good service, we have clients from more than dozens countries and regions, and we pride ourselves in providing our customers with a total satisfaction experiences.
We are doing our best to be your reliable partner for high quality Phytochemicals and Reference Standards from china.

Our main services:
A. Supply active ingredients and reference standards ofTraditional Chinese Medicine, from mgs to kgs scale.
B. Custom extraction and purification, target Herb Active Ingredients
C. Custom synthesis and semi-synthesis for Natural Active Ingredients
D. CR, CM and PD services from lab scale, pilot scale to commercial scale(GMP is also available)
E.Traditional Chinese Medicine compounds library

1.Provide traditional Chinese medicine reference materials and natural active ingredients;
2.More than 2200 compounds are available for selection, continuously building high-quality natural product libraries for drug research and development;
3.Provide various screening libraries and more inhibitor products;
4.Provide separation and structural determination of natural products;
5.Laboratory scale pilot to commercial scale collaborative research and process development services.More than 180 experiences in phytochemistry (still increasing)
Each product has passed very strict testing (NMR/MS/HPLC)
Agents from many countries

General tips：For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging：1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition：Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Details

Chemical Properties of Scopolamine

Cas No.	51-34-3	SDF
PubChem ID	153311	Appearance	Oil
Formula	C₁₇H₂₁NO₄	M.Wt	303.35
Type of Compound	Alkaloids	Storage	Desiccate at -20°C
Synonyms	Hyoscine; Scopine (-)-tropate; Scopine tropate
Solubility	Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
SMILES	CN1C2CC(CC1C3C2O3)OC(=O)C(CO)C4=CC=CC=C4
Standard InChIKey	STECJAGHUSJQJN-MKXJHAPZSA-N
Standard InChI	InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15?,16?/m1/s1
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging	1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment.
Shipping Condition	Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Scopolamine

The herbs of Atropa belladonna L.

Biological Activity of Scopolamine

Description

Scopolamine is a high affinity (nM) muscarinic antagonist. 5-HT3 receptor-responses are reversibly inhibited by Scopolamine with an IC50 of 2.09 μM. Scopolamine can cause learning and memory impairments and galantamine can reverse the symptom. It also can produce rapid and significant symptom improvement in patients with depression.

Targets

AChR | 5-HT3 receptor | M1 muscarinic receptor | M2 muscarinic receptor

In vivo

Rubus coreanus Miquel ameliorates scopolamine-induced memory impairments in ICR mice.[Pubmed: 25121635]

J Med Food. 2014 Oct;17(10):1049-56.

The present study investigated the effect of Rubus coreanus Miquel (RCM) on Scopolamine-induced memory impairments in ICR mice.
METHODS AND RESULTS:
Mice were orally administrated RCM for 4 weeks and Scopolamine was intraperitoneally injected into mice to induce memory impairment. RCM improved the Scopolamine-induced memory impairment in mice. The increase of acetylcholinesterase activity caused by Scopolamine was significantly attenuated by RCM treatment. RCM increased the levels of acetylcholine in the brain and serum of mice. The expression of choline acetyltransferase, phospho-cyclic AMP response element-binding protein, and phospho-extracellular signal-regulated kinase was significantly increased within the brain of mice treated with RCM. The brain antioxidant enzyme activity decreased by Scopolamine was increased by RCM.
CONCLUSIONS:
These results demonstrate that RCM exerts a memory-enhancing effect via the improvement of cholinergic function and the potentiated antioxidant activity in memory-impaired mice. The results suggest that RCM may be a useful agent for improving memory impairment.

Galantamine reverses scopolamine-induced behavioral alterations in Dugesia tigrina.[Pubmed: 24402079]

Invert Neurosci. 2014 Sep;14(2):91-101.

In planaria (Dugesia tigrina), Scopolamine, a nonselective muscarinic receptor antagonist, induced distinct behaviors of attenuated motility and C-like hyperactivity.
METHODS AND RESULTS:
Planarian locomotor velocity (pLMV) displayed a dose-dependent negative correlation with Scopolamine concentrations from 0.001 to 1.0 mM, and a further increase in Scopolamine concentration to 2.25 mM did not further decrease pLMV. Planarian hyperactivity counts was dose-dependently increased following pretreatment with Scopolamine concentrations from 0.001 to 0.5 mM and then decreased for Scopolamine concentrations ≥ 1 mM. Planarian learning and memory investigated using classical Pavlovian conditioning experiments demonstrated that Scopolamine (1 mM) negatively influenced associative learning indicated by a significant decrease in % positive behaviors from 86 % (control) to 14 % (1 mM Scopolamine) and similarly altered memory retention, which is indicated by a decrease in % positive behaviors from 69 % (control) to 27 % (1 mM Scopolamine). Galantamine demonstrated a complex behavior in planarian motility experiments since co-application of low concentrations of galantamine (0.001 and 0.01 mM) protected planaria against 1 mM Scopolamine-induced motility impairments; however, pLMV was significantly decreased when planaria were tested in the presence of 0.1 mM galantamine alone. Effects of co-treatment of Scopolamine and galantamine on memory retention in planaria via classical Pavlovian conditioning experiments showed that galantamine (0.01 mM) partially reversed Scopolamine (1 mM)-induced memory deficits in planaria as the % positive behaviors increased from 27 to 63 %.
CONCLUSIONS:
The results demonstrate, for the first time in planaria, Scopolamine's effects in causing learning and memory impairments and galantamine's ability in reversing Scopolamine-induced memory impairments.

Antidepressant treatment history as a predictor of response to scopolamine: clinical implications.[Pubmed: 24767003]

J Affect Disord. 2014 Jun;162:39-42.

The intravenous administration of Scopolamine produces rapid antidepressant effects. Generally, failing multiple previous antidepressant trials is associated with a poor prognosis for response to future medications. This study evaluated whether treatment history predicts antidepressant response to Scopolamine.
METHODS AND RESULTS:
Treatment resistant patients (2 failed medication trials) (n=31) and treatment naïve patients (no exposure to psychotropic medication) (n=31) with recurrent major depressive or bipolar disorder participated in a double-blind, placebo-controlled, crossover clinical trial. Following a placebo lead-in, participants randomly received P/S or S/P (P=3 placebo; S=3 Scopolamine (4ug/kg) sessions 3 to 5 days apart). The Montgomery-Asberg Depression Rating Scale (MADRS) was the primary outcome measure. A linear mixed model was used to examine the interaction between clinical response and treatment history, adjusting for baseline MADRS. Treatment resistant and treatment naïve subjects combined responded significantly to Scopolamine compared to placebo (F=15.06, p<0.001). Reduction in depressive symptoms was significant by the first post-Scopolamine session (F=42.75, p<0.001). A treatment history by Scopolamine session interaction (F=3.37, p=0.04) indicated treatment naïve subjects had lower MADRS scores than treatment resistant patients; this was significant after the second Scopolamine infusion (t=2.15, p=0.03). Post-hoc analysis: Also, we used a single regimen to administer Scopolamine, and smokers were excluded from the sample, limiting generalizability.
CONCLUSIONS:
Treatment naïve and treatment resistant patients showed improved clinical symptoms following Scopolamine, while those who were treatment naïve showed greater improvement. Scopolamine rapidly reduces symptoms in both treatment history groups, and demonstrates sustained improvement even in treatment resistant patients.

Protocol of Scopolamine

Animal Research

M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine.[Pubmed: 25187432]

J Pharmacol Exp Ther. 2014 Nov;351(2):448-56.

Scopolamine produces rapid and significant symptom improvement in patients with depression, and most notably in patients who do not respond to current antidepressant treatments. Scopolamine is a nonselective muscarinic acetylcholine receptor antagonist, and it is not known which one or more of the five receptor subtypes in the muscarinic family are mediating these therapeutic effects.
METHODS AND RESULTS:
We used the mouse forced-swim test, an antidepressant detecting assay, in wild-type and transgenic mice in which each muscarinic receptor subtype had been genetically deleted to define the relevant receptor subtypes. Only the M1 and M2 knockout (KO) mice had a blunted response to Scopolamine in the forced-swim assay. In contrast, the effects of the tricyclic antidepressant imipramine were not significantly altered by gene deletion of any of the five muscarinic receptors. The muscarinic antagonists biperiden, pirenzepine, and VU0255035 (N-[3-oxo-3-[4-(4-pyridinyl)-1-piper azinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide) with selectivity for M1 over M2 receptors also demonstrated activity in the forced-swim test, which was attenuated in M1 but not M2 receptor KO mice. An antagonist with selectivity of M2 over M1 receptors (SCH226206 [(2-amino-3-methyl-phenyl)-[4-[4-[[4-(3 chlorophenyl)sulfonylphenyl]methyl]-1-piperidyl]-1-piperidyl]methanone]) was also active in the forced-swim assay, and the effects were deleted in M2 (-/-) mice. Brain exposure and locomotor activity in the KO mice demonstrated that these behavioral effects of Scopolamine are pharmacodynamic in nature.
CONCLUSIONS:
These data establish muscarinic M1 and M2 receptors as sufficient to generate behavioral effects consistent with an antidepressant phenotype and therefore as potential targets in the antidepressant effects of Scopolamine.

Preparing Stock Solutions of Scopolamine

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	3.2965 mL	16.4826 mL	32.9652 mL	65.9304 mL	82.4131 mL
5 mM	0.6593 mL	3.2965 mL	6.593 mL	13.1861 mL	16.4826 mL
10 mM	0.3297 mL	1.6483 mL	3.2965 mL	6.593 mL	8.2413 mL
50 mM	0.0659 mL	0.3297 mL	0.6593 mL	1.3186 mL	1.6483 mL
100 mM	0.033 mL	0.1648 mL	0.3297 mL	0.6593 mL	0.8241 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.